CureVac N.V.

Total Valuation

CureVac N.V. carries a market capitalization of 1.05B, placing it among publicly traded companies globally. Its enterprise value stands at 676.22M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

CureVac N.V. currently has 225.17M shares outstanding.

Valuation Ratios

CureVac N.V. trades at a trailing price-to-earnings ratio of 5.35. The price-to-sales ratio is 2.03, and the price-to-book ratio stands at -0.70.

Enterprise Valuation

On an enterprise value basis, CureVac N.V. trades at an EV/EBITDA multiple of 2.97 and an EV/FCF ratio of 3.18. The EV/Sales ratio of 1.32 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 3.22 provides insight into valuation relative to core operating earnings.

Financial Position

CureVac N.V. maintains a current ratio of 6.17, meaning it holds 6.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 6.14, indicating elevated leverage, while an interest coverage ratio of 565.14 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, CureVac N.V. has paid 26.75M in income taxes, reflecting an effective tax rate of 12.14.

Stock Price Statistics

CureVac N.V.'s stock has gained approximately 23.60743% over the past 52 weeks. The 50-day moving average sits at 4.97, while the 200-day moving average is 4.85.

Income Statement

Over the trailing twelve months, CureVac N.V. generated 510.51M in revenue and converted that into 193.64M in net income, yielding earnings per share of 0.86. EBITDA reached 227.75M, while operating income came in at 209.95M.

Balance Sheet

CureVac N.V. holds 395.81M in cash and equivalents against 36.03M in total debt, resulting in a net debt position of -392.70M. Total book value stands at -1.49B, with working capital of 351.76M providing operational flexibility.

Cash Flow

CureVac N.V. produced 204.08M in operating cash flow over the past twelve months. After subtracting -7.93M in capital expenditures, free cash flow totaled 196.15M - equivalent to 0.87 per share.

Margins

CureVac N.V. operates with a gross margin of 94.81, reflecting its pricing power and cost economics. The operating margin of 41.13 and net profit margin of 37.93 provide insight into operational efficiency.

Dividends & Yields

Scores

CureVac N.V. posts an Altman Z-Score of 5.32, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.